Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer

Batool, Syeda Maheen; Hsia, Tiffaney; Beecroft, Alexandra; Lewis, Brian; Ekanayake, Emil; Rosenfeld, Yulia; Escobedo, Ana K.; Gamblin, Austin S.; Rawal, Siddarth; Cote, Richard J.; Watson, Mark; Wong, David T.W.; Patel, Abhijit A.; Skog, Johan; Papadopoulos, Nickolas; Bettegowda, Chetan; Castro, Cesar M.; Lee, Hakho; Srivastava, Sudhir; Carter, Bob S.; Balaj, Leonora

doi:10.1016/j.xcrm.2023.101196

Cited by 10 publications

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biological variability in biofluids poses additional challenges, and choosing the appropriate biofluid for biomarker discovery requires considering factors like tumor location and accessibility. Standardization in the preanalytical phase is key for ensuring the reproducibility and reliability of liquid biopsy studies [ 62 ].…”

Section: Introductionmentioning

confidence: 99%

Hodgkin lymphoma and liquid biopsy: a story to be told

Velasco-Suelto,

Gálvez-Carvajal,

Comino-Méndez

et al. 2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) represents a neoplasm primarily affecting adolescents and young adults, necessitating the development of precise diagnostic and monitoring tools. Specifically, classical Hodgkin lymphoma (cHL), comprising 90% of cases, necessitating tailored treatments to minimize late toxicities. Although positron emission tomography/computed tomography (PET/CT) has enhanced response assessment, its limitations underscore the urgency for more reliable progression predictive tools. Genomic characterisation of rare Hodgkin Reed-Sternberg (HRS) cells is challenging but essential. Recent studies employ single-cell molecular analyses, mass cytometry, and Next-Generation Sequencing (NGS) to unveil mutational landscapes. The integration of liquid biopsies, particularly circulating tumor DNA (ctDNA), extracellular vesicles (EVs), miRNAs and cytokines, emerge as groundbreaking approaches. Recent studies demonstrate ctDNA's potential in assessing therapy responses and predicting relapses in HL. Despite cHL-specific ctDNA applications being relatively unexplored, studies emphasize its value in monitoring treatment outcomes. Overall, this review underscores the imperative role of liquid biopsies in advancing HL diagnosis and monitoring.

show abstract

Section: Introductionmentioning

confidence: 99%